Category: EGFR

Background: This meta-analysis assessed the safety and effectiveness of retreatment with trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (HER2+MBC)

0 commentsEGFR

Background: This meta-analysis assessed the safety and effectiveness of retreatment with trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (HER2+MBC). second disease progression (HR =0.753; 95% CI: 0.548C1.035, em P /em 0.000).22 To avoid the heterogeneity of methodological limitation, we did not add these results to the pooled data. ….  Read More